National Research Corporation (NRC)
NASDAQ: NRC · Real-Time Price · USD
17.64
+0.22 (1.26%)
At close: Dec 12, 2025, 4:00 PM EST
17.36
-0.28 (-1.59%)
After-hours: Dec 12, 2025, 4:53 PM EST
National Research Market Cap
National Research has a market cap or net worth of $399.68 million as of December 12, 2025. Its market cap has decreased by -12.87% in one year.
Market Cap
399.68M
Enterprise Value
478.02M
1-Year Change
-12.87%
Ranking
Category
Stock Price
$17.64
Market Cap Chart
Since December 1, 1998, National Research's market cap has increased from $43.70M to $399.68M, an increase of 814.59%. That is a compound annual growth rate of 8.53%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Dec 12, 2025 | 399.70M | -3.48% |
| Dec 31, 2024 | 414.10M | -57.38% |
| Dec 29, 2023 | 971.50M | 5.48% |
| Dec 30, 2022 | 921.00M | -12.83% |
| Dec 31, 2021 | 1.06B | -2.32% |
| Dec 31, 2020 | 1.08B | -34.17% |
| Dec 31, 2019 | 1.64B | 73.99% |
| Dec 31, 2018 | 944.40M | -32.45% |
| Dec 29, 2017 | 1.40B | 33.39% |
| Dec 30, 2016 | 1.05B | 36.40% |
| Dec 31, 2015 | 768.40M | 20.06% |
| Dec 31, 2014 | 640.00M | -26.24% |
| Dec 31, 2013 | 867.70M | 133.57% |
| Dec 31, 2012 | 371.50M | 42.34% |
| Dec 30, 2011 | 261.00M | 14.32% |
| Dec 31, 2010 | 228.30M | 65.55% |
| Dec 31, 2009 | 137.90M | -28.88% |
| Dec 31, 2008 | 193.90M | 3.58% |
| Dec 31, 2007 | 187.20M | 19.69% |
| Dec 29, 2006 | 156.40M | 28.83% |
| Dec 30, 2005 | 121.40M | 4.93% |
| Dec 31, 2004 | 115.70M | -1.78% |
| Dec 31, 2003 | 117.80M | 72.73% |
| Dec 31, 2002 | 68.20M | 54.30% |
| Dec 31, 2001 | 44.20M | 57.30% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 903.78B |
| Johnson & Johnson | 505.98B |
| AbbVie | 395.86B |
| UnitedHealth Group | 305.02B |
| AstraZeneca | 282.91B |
| Novartis AG | 256.01B |
| Merck & Co. | 245.75B |
| Novo Nordisk | 223.42B |